A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Aoki, Ryo ^a,b   Kamikado, Kohei ^a   Suda, Wataru ^b,c   Takii, Hiroshi ^a   Mikami, Yumiko ^a   Suganuma, Natsuki ^a   Hattori, Masahira ^b,d   Koga, Yasuhiro ^e  

^a EZAKI GLICO CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d WASEDA UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; GLUCOSE; PROBIOTIC AGENT;

ANIMAL; BIFIDOBACTERIUM; DISEASE MODEL; GLUCOSE INTOLERANCE; INTESTINE FLORA; MALE; METABOLIC DISORDER; METABOLISM; METAGENOME; METAGENOMICS; MOUSE; PROCEDURES;

ACETATES; ANIMALS; BIFIDOBACTERIUM; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; GLUCOSE; GLUCOSE INTOLERANCE; MALE; METABOLIC DISEASES; METAGENOME; METAGENOMICS; MICE; PROBIOTICS;

EID: 85014429922     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43522     Document Type: Article

References (36)

1. Ley, R. E., Turnbaugh, P. J., Klein, S., Gordon, J. I. Microbial ecology: Human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
2. Cani, P. D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
3. Cani, P. D., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481 (2008).
4. Cani, P. D., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103 (2009).
5. Neyrinck, A. M., et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr. Diabetes 2, e28 (2012).
6. Everard, A., et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775-2786 (2011).
7. Zhang, X., et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci. Rep. 5 (2015).
8. Canfora, E. E., Jocken, J. W., Blaak, E. E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577-591 (2015).
9. Kimura, I., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 4, 1829 (2013).
10. Frost, G., et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).
11. McNelis, J. C., et al. GPR43 potentiates-cell function in obesity. Diabetes 64, 3203-3217 (2015).
12. Tolhurst, G., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364-371 (2012).
13. Kjems, L. L., Holst, J. J., Volund, A., Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386 (2003).
14. Zander, M., Madsbad, S., Madsen, J. L., Holst, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824-830 (2002).
15. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada: 2002. April, May. Guidelines for evaluation of probiotics in food. Available at: http://www. fda. gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219. pdf. (Accessed: 19/07/2016) (2008).
16. Yadav, H., Lee, J. H., Lloyd, J., Walter, P., Rane, S. G. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288, 25088-25097 (2013).
17. Yin, Y. N. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J. Gastroenterol. 16, 3394 (2010).
18. Wang, J., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 9, 1-15 (2015).
19. An, H., et al. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis. 10, 116 (2011).
20. Kondo, S., et al. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci. Biotechnol. Biochem. 74, 1656-1661 (2010).
21. Ishizuka, A., et al. Effects of administration of Bifidobacterium animalis subsp. lactis GCL2505 on defecation frequency and bifidobacterial microbiota composition in humans. J. Biosci. Bioeng. 113, 587-591 (2012).
22. Aoki, R., et al. Effect of Bifidobacterium animalis subsp. lactis GCL2505 on the physiological function of intestine in a rat model. Food Sci. Nutr. 4, 782-790 (2016).
23. Soccol, C. R., et al. The potential of probiotics: A review. Food Technol. Biotechnol. 48, 413-434 (2010).
24. Fukuda, S., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543-547 (2011).
25. Falcinelli, S., et al. Probiotic treatment reduces appetite and glucose level in the zebrafish model. Sci. Rep. 6, (2016).
26. Flint, H. J., Scott, K. P., Louis, P., Duncan, S. H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577-589 (2012).
27. Kimura, I., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. 108, 8030-8035 (2011).
28. Inoue, D., Tsujimoto, G., Kimura, I. Regulation of energy homeostasis by GPR41. Front. Endocrinol. (Lausanne). 5, 5-7 (2014).
29. Kimura, I., Inoue, D., Hirano, K., Tsujimoto, G. The SCFA receptor GPR43 and energy metabolism. Front. Endocrinol. (Lausanne). 5, 3-5 (2014).
30. Gutzwiller, J. P., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276, R1541-1544 (1999).
31. Turnbaugh, P. J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-131 (2006).
32. Lubura, M., et al. Non-invasive quantification of white and brown adipose tissues and liver fat content by computed tomography in mice. PLoS One 7, e37026 (2012).
33. Cani, P. D., Dewever, C., Delzenne, N. M. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br. J. Nutr. 92, 521 (2004).
34. Said, H. S., et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 21, 15-25 (2014).
35. Kim, S. W., et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 20, 241-253 (2013).
36. Tsuda, A., et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin. Transl. Gastroenterol. 6, e89 (2015).